Variable | Univariate p | HR (95% CI) | Multivariate p* | HR (95% CI) |
---|---|---|---|---|
CCI items p < 0.1 | ||||
 Chronic pulmonary disease | 0.046* | 0.61 (0.38–0.99) | 0.30 | 0.76 (0.45–1.28) |
 Peptic ulcer disease | 0.006* | 7.40 (1.80–30.50) | 0.17 | 2.75 (0.65–11.69) |
 Moderate/severe renal disease | 0.005* | 2.3 (1.29–4.13) | 0.005 | 2.46 (1.32–4.57) |
Comorbidities not included in CCI | ||||
 Hypertension | 0.54 | 0.93 (0.72–1.20) |  |  |
 Obesity | 0.32 | 0.77 (0.47–1.28) |  |  |
 Hyperlipidemia | 0.48 | 0.84 (0.51–1.37) |  |  |
Patient and treatment characteristics | ||||
 Age > 70 years | 0.19 | 0.84 (0.64–1.10) |  |  |
 CCI ≥ 3 | 0.41 | 1.15 (0.82–1.62) |  |  |
 Positive N stage of primary | 0.004* | 1.27 (1.08–1.50) | 0.25 | 1.11 (0.93–1.33) |
 Synchronous metastases | 0.036* | 1.36 (1.02–1.81) | 0.90 | 0.98 (0.71–1.35) |
 Metachronous lymph node metastases | 0.032* | 1.44 (1.03–2.00) | 0.17 | 1.31 (0.89–1.91) |
 Metachronous pulmonary metastases | 0.55 | 1.09 (0.83–1.43) |  |  |
 1st/2nd Line vs. 3rd Line treatment | 0.001* | 0.83 (0.77–0.90) | 0.30 | 0.89 (0.72–1.1) |
 Salvage treatment in Y90-RE | 0.001* | 2.17 (1.37–3.45) | < 0.001 | 4.35 (3.06–6.17) |